Findings

What do systematic reviews say?

102 questions · 102 findings · 46 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 56 · 54.9%GRADE not reported 10 · 9.8%Very low 14 · 13.7%Low 15 · 14.7%Moderate 4 · 3.9%High 3 · 2.9%

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 890 participants
High

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 744 participants
Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
450 participants
Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1870 participants
Very low

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

Quality of life · palliative participants with esophageal and GE‐junction carcinoma

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1129 participants
Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with AC of the esophagus

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1772 participants
Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Quality of life · palliative participants with SCC of the esophagus

1 finding from 1 review

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 156 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Quality of life: not measured · treatment of relapsed epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

Quality of life ‐ not reported · stage III and IV cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings 1: PLD with chemotherapy vs PLD alone

Quality of life · recurrent platinum‐resistant EOC

The review found no eligible studies for this question.

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Quality of Life ‐ not reportedÂ · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single‐dose intravesical chemotherapy instillation vs placebo or observation after nephroureterectomy

Disease‐specific quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Health status and quality of life · people with advanced gastric cancer

1 finding from 1 review

Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Quality of life at 12 months (

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 790 participants
Low

Probiotics vs placebo

Quality of life · participants with cancer treated with radiotherapy (with or without chemotherapy)

1 finding from 1 review

Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Low

Escalated BEACOPP vs chemotherapy including ABVD

Quality of life · Patients with early unfavourable or advanced stage HL

The review found no eligible studies for this question.

1 finding from 1 review

Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dexamethasone vs placebo

Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy,… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found